Somatogen (SMTG) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Somatogen (SMTG)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bharat H. Barai who wrote (250)	8/16/1997 11:51:00 AM
From: Ford Investor	of 442

Dr. Barai: I just happened to get off the phone with Nanita Waddell from Investor Relations (303-541-3311). I had asked her many questions regarding Somatogen's technology and whether it had any worth to its claims. She informed me of many things: 1) Somatogen is planning on having many articles and journals covering their Optro technology in the month of September. I feel this will be very positive for the company generating alot of interest among investors. SMTG is still an unknown when it comes to Wall Street. 2) She acknowledges that there are other companies that are producing other blood substitute products out there and that they will beat SMTG to the market. They plan on releasing their product in the year 2002. I had asked if there were any cases reported that had any problems with the product and she said NONE! Everyone loves using it from doctors to nurses to even patients who are looking for safety from diseases when it comes to using blood other than theirs. 3) She said that SMTG is in several talks with companies in regards to partnering with them. She claims that they will announce who it will be when the Phase II clinical trials are complete which will approximately be in the month of October. Could it possibly be the company that one of the board of directors is also a director on? 4) She claims the reason why SMTG got out of the Eli Lilly deal was because they were moving too slow in regarding to their testing. SMTG is currently conducting testing for hip replacement and cardio bypass surgeries. Lilly was exploring other less significant areas. 5) She did admit to the problem with the half life of the blood substitute and they are working on second generation of products for Optro to increase the half-life of the blood substitute so it stays in the body alot longer before metabolizing. 6) I asked about where she sees SMTG's stock price by January. Does $15 sound reasonable? She couldn't comment. She did make a point that the stock was trading before over $50/share. She felt very confident about the company's product. Think about it, this is the only product that this company is really positioned to market and make money on. There have been numerous scientists working on this technology for years and years. This product will either make them or break them. They are taking the necessary steps to reward their shareholders for this roller coaster ride in stock price. They adopted a shareholder's rights plan. I can picture it now: genetically engineered blood offered to hospitals free of AIDS, Hepatitis, and other diseases. A whole industry can be created from this product in which scientists have been working on over 50 years in a way to separate the hemoglobin from the red blood cells and allow it to have oxygen-carrying capabilities. Well good luck to all! Jeff, Rich, and Ron especially. :-)))))))))))

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next